- Home
- SJT vs RIGL Comparison
SJT vs RIGL Comparison
Compare SJT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- RIGL
- Stock Information
- Founded
- SJT 1980
- RIGL 1996
- Country
- SJT United States
- RIGL United States
- Employees
- SJT N/A
- RIGL N/A
- Industry
- SJT Oil & Gas Production
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- SJT Energy
- RIGL Health Care
- Exchange
- SJT Nasdaq
- RIGL Nasdaq
- Market Cap
- SJT 296.0M
- RIGL 335.5M
- IPO Year
- SJT N/A
- RIGL 2000
- Fundamental
- Price
- SJT $6.39
- RIGL $20.97
- Analyst Decision
- SJT
- RIGL Buy
- Analyst Count
- SJT 0
- RIGL 5
- Target Price
- SJT N/A
- RIGL $36.40
- AVG Volume (30 Days)
- SJT 333.7K
- RIGL 217.1K
- Earning Date
- SJT 05-15-2025
- RIGL 08-05-2025
- Dividend Yield
- SJT N/A
- RIGL N/A
- EPS Growth
- SJT N/A
- RIGL N/A
- EPS
- SJT 0.02
- RIGL 2.08
- Revenue
- SJT $1,931,777.00
- RIGL $203,077,000.00
- Revenue This Year
- SJT N/A
- RIGL $14.41
- Revenue Next Year
- SJT N/A
- RIGL $15.97
- P/E Ratio
- SJT $276.42
- RIGL $10.14
- Revenue Growth
- SJT N/A
- RIGL 70.16
- 52 Week Low
- SJT $3.21
- RIGL $7.48
- 52 Week High
- SJT $7.22
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- SJT 50.78
- RIGL 61.71
- Support Level
- SJT $6.28
- RIGL $18.63
- Resistance Level
- SJT $7.22
- RIGL $20.99
- Average True Range (ATR)
- SJT 0.30
- RIGL 1.07
- MACD
- SJT -0.07
- RIGL 0.11
- Stochastic Oscillator
- SJT 23.39
- RIGL 82.81
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.